AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15536462
Drug: St John's
RxNorm normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St John's wort (300 mg three times daily)
Trial: 15536462
Drug: Imipramine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (50 mg three times daily)
Trial: 11699402
Drug: Cefpirome (CPO)
RxNorm normalized name: Cefpirome
DrugBank: Cefpirome (DB13682)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome (CPO) 2 g x 2/day
Trial: 11699402
Drug: Piperacillin-tazobactam (PT)
RxNorm normalized name: piperacillin / tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin-tazobactam (PT) 4 g x 3/day
Trial: 8501490
Drug: Sequential Postremission
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Postremission Chemotherapy (SPC)
Trial: 29450870
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (propranolol, amitriptyline, flunarizine, topiramate)
Trial: 26331608
Drug: Basal or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal or poststimulated 17OHP ≥30 nmol/l (group A)
Trial: 26331608
Drug: Poststimulated 17OHP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poststimulated 17OHP <30 nmol/l (group B)
Trial: 25397800
Drug: 0.7-mm machined-collar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7-mm machined-collar implants
Trial: 25397800
Drug: 1.5-mm machined-collar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5-mm machined-collar implants
Trial: 20672994
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) once-daily (QD) with tenofovir DF and emtricitabine
Trial: 20672994
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) twice-daily (BID) with tenofovir DF and emtricitabine
Trial: 20672994
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) once-daily (QD)
Trial: 20672994
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) twice-daily (BID)
Trial: 30004141
Drug: Regulations limiting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regulations limiting exposure to unwanted drones; specific details on dosage and duration not applicable.
Trial: 30004141
Drug: Regulations hampering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regulations hampering drones used for public safety; specific details on dosage and duration not applicable.
Trial: 30004141
Drug: Regulations protecting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regulations protecting personal privacy; specific details on dosage and duration not applicable.
Trial: 30290902
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin at 1.8 mg/kg via intravenous infusion once every 3 weeks for up to 16 cycles (recommended phase 2 dose).
Trial: 30290902
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin at 1.8 mg/kg.
Trial: 22220931
Drug: Berberine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine (300 mg, t.i.d., for 30 days)
Trial: 17112401
Drug: TAU+OT (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU+OT (treatment as usual plus occupational therapy)
Trial: 16148823
Drug: Standard-dose epinephrine
RxNorm normalized name: epinephrine Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose epinephrine
Trial: 10983527
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg single dose
Trial: 10983527
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg two doses on 2 consecutive days
Trial: 1976576
Drug: Sulphasalazine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphasalazine treatment for four weeks
Trial: 1976576
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid treatment for four weeks
Trial: 1976576
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment after sulphasalazine
Trial: 27855998
Drug: Teduglutide 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teduglutide 0.05 mg/kg/d
Trial: 23333663
Drug: Teduglutide 0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teduglutide 0.10 mg/kg/d
Trial: 23333663
Drug: Teduglutide (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teduglutide (both doses)
Trial: 15586183
Drug: Psycho-educative group-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psycho-educative group-based treatment programme (8 weeks, weekly sessions of 2.5 hours, booster sessions after 1, 2, and 4 months)
Trial: 1849159
Drug: Topical ACV
RxNorm normalized name: ACV tripeptide
DrugBank: ACV tripeptide (DB02025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ACV (started 5 min after UVR)
Trial: 6277698
Drug: Cyclic estrogen
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic estrogen regimen (0.625 mg of conjugated estrogens, 3 weeks on, 1 week off)
Trial: 6277698
Drug: Continuous estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous estrogen regimen (0.625 mg of conjugated estrogens, daily)
Trial: 26682998
Drug: Omega-3 and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 and omega-6 supplements for 12 weeks
Trial: 21182509
Drug: FSL phototherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FSL phototherapy (twice per week for 4 weeks)
Trial: 19947442
Drug: Sublingual nimesulide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nimesulide
Trial: 17511722
Drug: PSA <
RxNorm normalized name: Prostate-Specific Antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA < 4 ng/mL with doubtful DRE finding
Trial: 11437873
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine (10 mL h(‐1))
Trial: 11437873
Drug: 0.2% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine (10 mL h(‐1))
Trial: 11437873
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine with 0.5 microg mL(‐1) sufentanil (BS)
Trial: 11437873
Drug: 0.2% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine with 0.5 microg mL(‐1) sufentanil (RS)
Trial: 11437873
Drug: 0.5 microg
RxNorm normalized name: calcitriol 0.5 MICROGRAM In 1 CAPSULE ORAL CAPSULE, LIQUID FILLED [Rocaltrol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 microg mL(‐1) sufentanil only (S)
Trial: 9881243
Drug: Sulphonylurea treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphonylurea treatment
Trial: 27029390
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for chronic progressive diseases (specific intervention details not available)
Trial: 25545540
Drug: Esmolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (100 μg/kg per min for 10 mins, then 50 μg/kg per min for 50 mins)
Trial: 25545540
Drug: Tecadenoson (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tecadenoson (75 μg)
Trial: 25545540
Drug: Tecadenoson (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tecadenoson (300 μg)
Trial: 22562973
Drug: Methotrexate monotherapy
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate monotherapy (PBO+MTX)
Trial: 3096035
Drug: Terbutaline (T)
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terbutaline (T) infusion
Trial: 26586786
Drug: MTP-131 infused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTP-131 infused at a rate of 0.05 mg/kg/h for 1 h
Trial: 24145543
Drug: Ganciclovir at
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganciclovir at 5 mg/kg body weight intravenously
Trial: 24145543
Drug: Ganciclovir dose
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganciclovir dose of 2.5 mg/kg once daily
Trial: 22001666
Drug: Music intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Music intervention (at least 2 daily sessions of music listening between D0 and D10, continued at home until D60)
Trial: 18763685
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (2.5% lidocaine/2.5% prilocaine)
Trial: 18763685
Drug: Oraqix thermosetting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oraqix thermosetting gel (2.5% lidocaine/2.5% prilocaine)
Trial: 16053244
Drug: Pharmaceutical grade
RxNorm normalized name: CVS Pharmaceutical Grade Fish Oil 1000mg Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical grade tryptophan with carbohydrate
Trial: 2139413
Drug: vehicle 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle 0.9% NaCl40 ml and 20% albumin 5 ml
Trial: 6992833
Drug: Ro 10-9359
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 10-9359 (100 mg daily initially, maintenance dose 50 mg)
Trial: 24806030
Drug: Acarbose/metformin 50/500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose/metformin 50/500 mg FDC (test)
Trial: 24806030
Drug: Acarbose 50
RxNorm normalized name: acarbose 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 50 mg and metformin 500 mg as loose combination (reference)
Trial: 24806030
Drug: Acarbose/metformin FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose/metformin FDC and loose combination
Trial: 16344839
Drug: MAS XR
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MAS XR 20‐60 mg/day
Trial: 12170853
Drug: ITI implant
RxNorm normalized name: Arthur Itis
DrugBank: Trolamine salicylate (DB11079)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ITI implant system
Trial: 12170853
Drug: Steri-Oss implant
RxNorm normalized name: BANDAGE,STERI-STRIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steri-Oss implant system
Trial: 12170853
Drug: Southern implant
RxNorm normalized name: Fluzone 2025 Southern Hemisphere
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Southern implant system
Trial: 8552232
Drug: Baclofen (GABAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (GABAB receptor agonist) administered pre-operatively with morphine (mu-opioid analgesic)
Trial: 8552232
Drug: Baclofen (GABAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (GABAB receptor agonist) administered with pentazocine (kappa-opioid analgesic)
Trial: 8552232
Drug: Pentazocine (kappa-opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine (kappa-opioid analgesic)
Trial: 27552802
Drug: Educational session
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational session focusing on the importance of adherence to medication (30 minutes)
Trial: 22829691
Drug: Low-dose etanercept
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose etanercept (25 mg/week)
Trial: 22829691
Drug: Standard-dose etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard-dose etanercept (50 mg/week)
Trial: 22829691
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Low-dose and Standard-dose etanercept)
Trial: 20833514
Drug: Olanzapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (mean dose 10.9 mg)
Trial: 20833514
Drug: Ziprasidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (mean dose 88.9 mg)
Trial: 20833514
Drug: Olanzapine to
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine to Ziprasidone switch (mean dose 136 mg)
Trial: 20833514
Drug: Ziprasidone to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone to Olanzapine switch (mean dose 16 mg)
Trial: 26427866
Drug: Lidocaine with
RxNorm normalized name: Lidocaine with Tegaderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine with clonidine (LC; 15 mcg/ml)
Trial: 26427866
Drug: Lidocaine with
RxNorm normalized name: Lidocaine with Tegaderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine with epinephrine (LE; 1:80,000) and Lidocaine with clonidine (LC; 15 mcg/ml)
Trial: 10769603
Drug: Phyllanthus amarus
RxNorm normalized name: Phyllanthus amarus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phyllanthus amarus (300 mg capsules, 3 capsules thrice daily)
Trial: 10769603
Drug: Placebo (antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (antacid powder in similar capsule form)
Trial: 6846115
Drug: Acebutolol (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (both doses)
Trial: 15788107
Drug: 375 ml
RxNorm normalized name: isopropyl alcohol 0.0375 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 ml red wine daily for 2 weeks
Trial: 1835850
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with cisplatin
Trial: 7039400
Drug: Terbutaline depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline depot tablets 7.5 mg twice a day
Trial: 7039400
Drug: Terbutaline tablets
RxNorm normalized name: terbutaline Oral Tablet
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terbutaline tablets 5 mg three times a day
Trial: 31727415
Drug: Dienogest 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dienogest 0.5 mg/d
Trial: 31727415
Drug: Dienogest 1
RxNorm normalized name: Dienogest
DrugBank: Dienogest (DB09123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dienogest 1 mg/d
Trial: 31727415
Drug: Dienogest 2
RxNorm normalized name: dienogest 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dienogest 2 mg/d
Trial: 31727415
Drug: Ethinylestradiol 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinylestradiol 0.02 mg/drospirenone 3 mg (reference drug)
Trial: 27419081
Drug: Ginger powder
RxNorm normalized name: Emergen-C Turmeric & Ginger Powder for Solution (Citrus-Ginger)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger powder supplementation (1 g/d)
Trial: 27419081
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mg starch)
Trial: 20726255
Drug: OPV (HDC)
RxNorm normalized name: Opvee
DrugBank: Oral Polio Vaccine (DB15864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPV (HDC) vaccine
Trial: 16171661
Drug: Hypotensive total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotensive total intravenous anesthesia (HTIVA) with propofol and remifentanil (n = 20)
Trial: 12606177
Drug: Buprenorphine (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (16 mg sublingually for 12 months; supervised daily administration for at least 6 months, possible take-home doses thereafter)
Trial: 10531156
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) by pMDI, 1.76 mg (250 microg ex-valve, 220 microg ex-actuator)
Trial: 10531156
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) by pMDI with 750-mL spacer
Trial: 1834093
Drug: Enalapril (5‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5‐20 mg daily)
Trial: 7035545
Drug: Sequential Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential Spironolactone
Trial: 7035545
Drug: Combination (spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (spironolactone and furosemide)
Trial: 25453457
Drug: Aspirin 325
RxNorm normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325 mg plus clopidogrel 75 mg
Trial: 25453457
Drug: Aspirin 325
RxNorm normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325 mg plus placebo
Trial: 21336429
Drug: Eicosapentaenoic Acid‐enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic Acid‐enriched oral nutritional supplement (2 packs per day for 12 weeks) plus dietary counseling
Trial: 15920225
Drug: HES 264/0.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES 264/0.45 (up to 45 mL/kg)
Trial: 15920225
Drug: 5% albumin
RxNorm normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% albumin (up to 45 mL/kg)
Trial: 9669185
Drug: Fluvoxamine 100
RxNorm normalized name: fluvoxamine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine 100 mg a day
Trial: 2374564
Drug: Active injections
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active injections of suspected allergens (60 total injections)
Trial: 2374564
Drug: Control injections
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control injections (180 total injections)
Trial: 2374564
Drug: Neutralizing doses
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralizing doses given by physicians (both suspected allergen and saline)
Trial: 16635
Drug: Dichloralphenazone 1300
RxNorm normalized name: Dichloralphenazone
DrugBank: Dichloralphenazone (DB01495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichloralphenazone 1300 mg
Trial: 28239939
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sitagliptin 100 mg plus fasiglifam 25 mg
Trial: 28239939
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sitagliptin 100 mg plus fasiglifam 50 mg
Trial: 28239939
Drug: Fasiglifam 25
RxNorm normalized name: Fasiglifam
DrugBank: Fasiglifam (DB12491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasiglifam 25 mg monotherapy
Trial: 28239939
Drug: Fasiglifam 50
RxNorm normalized name: Fasiglifam
DrugBank: Fasiglifam (DB12491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasiglifam 50 mg monotherapy
Trial: 17276718
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine administered at dinner (n=589)
Trial: 17276718
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine administered at bedtime (n=589)
Trial: 17276718
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine at dinner (FAA subgroup)
Trial: 17276718
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine at bedtime (FAA subgroup)
Trial: 17276718
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine at dinner (RHI subgroup)
Trial: 17276718
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine at bedtime (RHI subgroup)
Trial: 11317534
Drug: Breast conserving
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast conserving treatment (quandrantectomy + radiation)
Trial: 9681665
Drug: Topical aspirin/diethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical aspirin/diethyl ether (ADE) mixture (750 mg)
Trial: 9681665
Drug: Oral aspirin
RxNorm normalized name: aspirin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral aspirin (500 mg)
Trial: 7927958
Drug: Policosanol 5
RxNorm normalized name: policosanol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 5 mg once-a-day for 8 weeks
Trial: 7927958
Drug: Policosanol 5
RxNorm normalized name: policosanol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 5 mg twice-a-day for 8 weeks
Trial: 7927958
Drug: Policosanol 10
RxNorm normalized name: policosanol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 10 mg twice-a-day for 8 weeks